Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer

British Journal of Cancer

Volumn 100, Issue 6, 2009, Pages 959-970

  Loddo, M ^a   Kingsbury, S R ^b   Rashid, M ^a   Proctor, I ^a   Holt, C ^c   Young, J ^c   El Sheikh, S ^a   Falzon, M ^a   Eward, K L ^c   Prevost, T ^a,d   Sainsbury, R ^e   Stoeber, K ^a,b   Williams, G H ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e PRINCESS ANNE HOSPITAL   (United Kingdom)

Author keywords

Aneuploidy; Aurora A; Breast cancer; DNA replication licensing; Predictive testing; Prognosis

Indexed keywords

AURORA A KINASE; CISPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FLUOROURACIL; GEMININ; HISTONE H3; HYDROXYUREA; METHOTREXATE; MINICHROMOSOME MAINTENANCE PROTEIN 2; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; POLO LIKE KINASE 1; STAUROSPORINE;

ADULT; ARTICLE; BREAST CANCER; CANCER RELAPSE; CANCER RISK; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIVISION; CONTROLLED STUDY; DISEASE COURSE; DNA REPLICATION; DRUG MECHANISM; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; DNA, NEOPLASM; FEMALE; GENOMIC INSTABILITY; HUMANS; KI-67 ANTIGEN; PHENOTYPE; PLOIDIES; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES;

EID: 62549147488     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604924     Document Type: Article

References (57)

1. Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjällskog ML, Blomqvist C (2007) Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 51: 491- 498
2. Anonymous (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717
3. Anonymous (2007) Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. J Natl Cancer Inst 99: 506-515
4. Barkley LR, Hong HK, Kingsbury SR, James M, Stoeber K, Williams GH (2007) Cdc6 is a rate-limiting factor for proliferative capacity during HL60 cell differentiation. Exp Cell Res 313: 3789-3799
5. Blow JJ, Hodgson B (2002) Replication licensing - defining the proliferative state? Trends Cell Biol 12: 72-78
6. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334
7. Crosio C, Fimia GM, Loury R, Kimura M, Okano Y, Zhou H, Sen S, Allis CD, Sassone-Corsi P (2002) Mitotic phosphorylation of histone H3: spatiotemporal regulation by mammalian Aurora kinases.Mol Cell Biol 22: 874-885
8. De Azambuja E, Cardoso F, De Castro Jr G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer 96: 1504- 1513
9. Dudderidge TJ, Stoeber K, Loddo M, Atkinson G, Fanshawe T, Griffiths DF, Williams GH (2005) Mcm2, geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 11: 2510- 2517
10. Dunkler D, Michiels S, Schemper M (2007) Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer 43: 745-751
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (1998a) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930 -942
12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (1998b) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467
13. Ellis PA, Barrett-Lee PJ, Bloomfield D, Cameron DA, Hall E, Johnson L, Johnston SRD, Bliss JM (2007) Preliminary results of the UK Taxotere as Adjuvant Chemotherapy (TACT) Trial. Breast Cancer Res Treat 106(Suppl 1): Abstract 78
14. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410
15. Eward KL, Obermann EC, Shreeram S, Loddo M, Fanshawe T, Williams C, Jung HI, Prevost AT, Blow JJ, Stoeber K, Williams GH (2004) DNA replication licensing in somatic and germ cells. J Cell Sci 117: 5875- 5886
16. Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH, Coleman N (1999) Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 5: 2121- 2132
17. Gonzalez MA, Tachibana KE, Chin SF, Callagy G, Madine MA, Vowler SL, Pinder SE, Laskey RA, Coleman N (2004) Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol 204: 121-130
18. Gonzalez MA, Tachibana KE, Laskey RA, Coleman N (2005) Control of DNA replication and its potential clinical exploitation. Nat Rev Cancer 5: 135-141
19. Gown AM (2008) Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21(Suppl 2): S8-S15
20. Gurley LR, D'Anna JA, Barham SS, Deaven LL, Tobey RA (1978) Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem 84: 1-15
21. Haroske G, Giroud F, Reith A, Bocking A (1998) 1997 ESACP consensus report on diagnostic DNA image cytometry. Part I: basic considerations and recommendations for preparation, measurement and interpretation. European Society for Analytical Cellular Pathology. Anal Cell Pathol 17: 189-200
22. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474- 1481
23. Hook SS, Lin JJ, Dutta A (2007) Mechanisms to control rereplication and implications for cancer. Curr Opin Cell Biol 19: 663-671
24. Keen N, Taylor S (2004) Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4: 927- 936
25. Kingsbury SR, Loddo M, Fanshawe T, Obermann EC, Prevost AT, Stoeber K, Williams GH (2005) Repression of DNA replication licensing in quiescence is independent of geminin and may define the cell cycle state of progenitor cells. Exp Cell Res 309: 56-67
26. Kulkarni AA, Loddo M, Leo E, Rashid M, Eward KL, Fanshawe TR, Butcher J, Frost A, Ledermann JA, Williams GH, Stoeber K (2007) DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma. Clin Cancer Res 13: 6153- 6161
27. Machida YJ, Hamlin JL, Dutta A (2005) Right place, right time, and only once: replication initiation in metazoans. Cell 123: 13-24
28. Michiels S, Koscielny S, Hill C (2005) Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365: 488-492
29. Michiels S, Koscielny S, Hill C (2007) Interpretation of microarray data in cancer. Br J Cancer 96: 1155-1158
30. Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2: 21-32
31. Obermann EC, Eward KL, Dogan A, Paul EA, Loddo M, Munson P, Williams GH, Stoeber K (2005) DNA replication licensing in peripheral B-cell lymphoma. J Pathol 205: 318-328
32. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817- 2826
33. Paulson JR, Taylor SS (1982) Phosphorylation of histones 1 and 3 and nonhistone high mobility group 14 by an endogenous kinase in HeLa metaphase chromosomes. J Biol Chem 257: 6064-6072
34. Perou CM, Jeffrey SS, van de RM, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, Brown PO, Botstein D (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96: 9212-9217
35. Planas-Silva MD, Weinberg RA (1997) The restriction point and control of cell proliferation. Curr Opin Cell Biol 9: 768-772
36. Plyte S, Musacchio A (2007) PLK1 inhibitors: setting the mitotic death trap. Curr Biol 17: R280-R283
37. Poole CJ, Hiller L, Howard HC, Dunn JA, Canney P, Wardley AM, Kennedy MJ, Coleman RE, Leonard RC, Earl HM, tAnGo trial collaborators (2008) tAnGo: a randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). J Clin Oncol 26 (Suppl 1): Abstract 506
38. Rampaul RS, Pinder SE, Elston CW, Ellis IO (2001) Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham Breast Team. Eur J Surg Oncol 27: 229-238
39. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, van de RM, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24: 227- 235
40. Sherr CJ, Roberts JM (2004) Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18: 2699-2711
41. Shetty A, Loddo M, Fanshawe T, Prevost AT, Sainsbury R, Williams GH, Stoeber K (2005) DNA replication licensing and cell cycle kinetics of normal and neoplastic breast. Br J Cancer 93: 1295-1300
42. Shima N, Alcaraz A, Liachko I, Buske TR, Andrews CA, Munroe RJ, Hartford SA, Tye BK, Schimenti JC (2007) A viable allele of Mcm4 causes chromosome instability and mammary adenocarcinomas in mice. Nat Genet 39: 93-98
43. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de RM, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein LP, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874
44. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100: 8418-8423
45. Sotiriou C, Piccart MJ (2007) Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 7: 545-553
46. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272
47. Stoeber K, Mills AD, Kubota Y, Krude T, Romanowski P, Marheineke K, Laskey RA, Williams GH (1998) Cdc6 protein causes premature entry into S phase in a mammalian cell-free system. EMBO J 17: 7219-7229
48. Stoeber K, Tlsty TD, Happerfield L, Thomas GA, Romanov S, Bobrow L, Williams ED, Williams GH (2001) DNA replication licensing and human cell proliferation. J Cell Sci 114: 2027-2041
49. Subramaniam DS, Isaacs C (2005) Utilizing prognostic and predictive factors in breast cancer. Curr Treat Options Oncol 6: 147- 159
50. Tachibana KE, Gonzalez MA, Coleman N (2005) Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol 205: 123-129
51. Van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der KK, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536
52. Wei Y, Yu L, Bowen J, Gorovsky MA, Allis CD (1999) Phosphorylation of histone H3 is required for proper chromosome condensation and segregation. Cell 97: 99-109
53. Wharton SB, Hibberd S, Eward KL, Crimmins D, Jellinek DA, Levy D, Stoeber K, Williams GH (2004) DNA replication licensing and cell cycle kinetics of oligodendroglial tumours. Br J Cancer 91: 262- 269
54. Whitfield ML, George LK, Grant GD, Perou CM (2006) Common markers of proliferation. Nat Rev Cancer 6: 99-106
55. Williams GH, Stoeber K (2007) Cell cycle markers in clinical oncology. Curr Opin Cell Biol 19: 672-679
56. Wohlschlegel JA, Kutok JL, Weng AP, Dutta A (2002) Expression of geminin as a marker of cell proliferation in normal tissues and malignancies. Am J Pathol 161: 267-273
57. Zetterberg A, Larsson O (1985) Kinetic analysis of regulatory events in G1 leading to proliferation or quiescence of Swiss 3T3 cells. Proc Natl Acad Sci USA 82: 5365-5369